Please assess the completion status of the following clinical trial:

Trial Title: The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of chylomicronemia~* A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia)~* Fasting triglycerides (TG) ≥ 750 mg/dL (8.4 mmol/L) at Screening~Exclusion Criteria:~* Diabetes mellitus if newly diagnosed or if HbA1c ≥ 9.0%~* Other types of severe hypertriglyceridemia~* Active pancreatitis within 4 weeks of screening~* Acute Coronary Syndrome within 6 months of screening~* Major surgery within 3 months of screening~* Treatment with Glybera therapy within 2 years of screening~* Previous treatment with IONIS-APOCIIIRx~* Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
- Volanesorsen (Type: EXPERIMENTAL): Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).